louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02331186: Effects of Bariatric Surgery on Pelvic Floor Fonctions in Obese Women
Official title: Effects of Bariatric Surgery on Pelvic Floor in Obese Women
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Urinary Incontinence
Obesity
Keywords: Obesity
Bariatric surgery
Urinary incontinence
Pelvic floor
Lead sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Sponsor class: OTHER_GOV
First posted: 2015-01-06
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: women who underwent bariatric surgery Body mass index ≥ 40 kg/m2 \>18 years old

Brief summary: Urinary incontinence is well documented as a comorbidity of obesity. Studies demonstrate improvement of incontinency after weight loss. However, the mechanisms are still not clear. Aim of our study to analyze the effects of bariatric surgery on pelvic floor function in women.

Detailed description: Obesity is considered an important public health problem, both in developed and developing countries. Obese people are at a higher risk for developing various comorbidities: type II diabetes, dyslipidemia, cardiovascular and cerebrovascular diseases, coagulation disorders, degenerative joint disease, some types of cancer, sleep apnea and urinary incontinence Women suffering from obesity are more likely to develop urinary incontinence, especially when related to stress. Excess weight is a modifiable risk factor. It is believed that weight reduction may be an effective treatment for urinary incontinence. The aim of this study is to analyze the effects of weight loss induced by bariatric surgery on pelvic floor function. Taking into account that modest weight loss (5% to 10%) already brings benefits to women with obesity and incontinence, one may assume even more marked improvement owing to the massive loss of weight by surgical means.

Eligibility criteria: Inclusion Criteria:

* Body mass index ≥ 40 kg/m2
* \>18 years old
* participants who provided written informed consent

Exclusion Criteria:

* History of gynecologic operation time under one year
* History of pelvic physiotherapy
* Chronic obstructif lung disease
* Norologic disease
* Women in menopause

Primary outcomes:
measure: urodynamic parameters
timeFrame: after six month
Secondary outcomes:
measure: Urinary incontinence
timeFrame: after six month
measure: oxford scales
timeFrame: after six month
measure: health quality scores
timeFrame: after six month
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Bakirkoy Dr Sadi Konuk Training and Research Hospital
state: Bakirkoy
city: Istanbul
country: Turkey
facility: Bakirkoy Dr. Sadi Konuk Teaching and Research Hospital
Study officials:
References:
Clinical trial NCT05221086: Urdu Version Of ProFitMap-Neck Questionnaire In Population With Chronic Neck Pain A Reliability And Validity Study
Official title: Urdu Version of The ProFitMap-neck - Reliability and Validity of a Questionnaire for Measuring Symptoms and Functional Limitations in Chronic Neck Pain
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Neck Pain
Keywords: Urdu Version of ProFitMap-neck
Non-specific Chronic Neck Pain
Psychometric Properties
Validity
Functional Limitations
Reliability
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2022-02-02
Enrollment: 136
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pakistani Population with non-specific Chronic Neck Pain.

Brief summary: The aim of this study is to translate or culturally adapt ProFitMap-neck into Urdu language and to investigate the reliability and validity of the ProFitMap-neck in Pakistani population having chronic neck pain. Also check it's correlation with Neck Disability Index.

Detailed description: As with prior suggestions, the English version of the ProFitMap-neck will be translated and culturally modified.In population having Chronic Neck Pain ProFitMap-neck will be distributed among one hundred and thirty six participants selected by a convenience sampling technique based on pre-defined inclusion and exclusion criteria.The questionnaire will be filled out by two observers on the same day to examine inter and intra-observer reliability of the final ProFitMap-neck and neck disability index. For the inter-observer evaluation, there will be a 2 hour delay between the first and second application. After 7 days, observer-1 will conduct a third assessment (re-testing) for intra-observer evaluation.The Statistical Package of Social Sciences program will be used to examine the data.

Eligibility criteria: Inclusion Criteria

Non-specific chronic neck pain Age 18-65 years Neck pain that isn't caused by a traumatic event

Exclusion Criteria

Neck pain due to any type of surgery Neck pain as a result of an injury Neck pain due to broken bone or dislocation Rheumatological issues Pregnant women Any Cardiovascular disorders Any Neurological problems Cord compression Insufficiency of the vertebrobasilar artery

Primary outcomes:
measure: ProFitMap-Neck Questionnaire
timeFrame: 1st day
measure: Neck Pain Disability Index
timeFrame: 1st day
Secondary outcomes:
Other outcomes:
Locations:
city: Faisalabad
country: Pakistan
facility: Ripah International University
state: Punjab
Study officials:
affiliation: Riphah International University
name: Muhammad Kashif
role: STUDY_CHAIR
References:
Clinical trial NCT00491686: AZD6765 for Treatment Resistant Depression
Official title: A Phase IIa, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Depression
Keywords: Long-term depression
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2007-06-26
Enrollment: 34
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of Depression
* Inadequate response to an adequate course of antidepressants

Exclusion Criteria:

* Psychiatric disorder other than depression
* Pregnancy or lactation
* Current diagnosis of cancer

Primary outcomes:
measure: The primary objective is to determine whether an antidepressant effect can be achieved in patients with Treatment Resistant Depression determined by a change from baseline in the MADRS total score.
timeFrame: Change from Baseline
Secondary outcomes:
measure: The secondary objective is to assess the safety and tolerability of AZD6765 as assessed by vital signs, physical examination, clinical laboratory evaluations, ECG's and incidence of adverse events.
timeFrame: each visit; change from baseline
Other outcomes:
Locations:
city: Glendale
country: United States
facility: Research Site
state: California
city: Hartford
country: United States
facility: Research Site
state: Connecticut
city: New Haven
country: United States
facility: Research Site
state: Connecticut
city: Wichita
country: United States
facility: Research Site
state: Kansas
city: Rockville
country: United States
facility: Research Site
state: Maryland
Study officials:
affiliation: AstraZeneca
name: Mark Smith, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Dean RL, Hurducas C, Hawton K, Spyridi S, Cowen PJ, Hollingsworth S, Marquardt T, Barnes A, Smith R, McShane R, Turner EH, Cipriani A. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3.
citation: Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, Quirk MC. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2014 Sep;19(9):978-85. doi: 10.1038/mp.2013.130. Epub 2013 Oct 15.
Clinical trial NCT06166186: Effect of Intraoperative Music on Inflammatory Response in Donor Hepatectomy
Official title: Effect of Intraoperative Music on Inflammatory Response in Adult Living Donor Hepatectomy.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Transplantation
Hepatectomy
Music
Stress Response
Lead sponsor: Istinye University
Sponsor class: OTHER
Collaborators: name: The Scientific and Technological Research Council of Turkey
First posted: 2023-12-12
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: It has been reported that non-pharmacological methods can be used as an alternative in addition to pharmacological methods to reduce pain, anxiety, stress and inflammatory response that begins with the surgical incision in the intraoperative period and continues throughout the operation. It has been reported that music can be used as an alternative non-pharmacological method to reduce pain and anxiety in the perioperative period, as well as surgical stress and the related stress response.

The aim of this study is to test the hypothesis that music used as a non-pharmacological method in the intraoperative period can reduce inflammatory response in living donor hepatectomy.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing donor hepatectomy
* American Society of Anesthesiologists class 1 to 2
* Ability to consent

Exclusion Criteria:

* American Society of Anesthesiologists greater than 2
* Documented or known sensitivity to any drug to be used in the study.
* Patient with immunosuppressant/ cytotoxic/ steroid therapy.
* not understand the aim and objectives of the study

Primary outcomes:
measure: Differences in Interleukin-6 (IL-6)
timeFrame: 4 hours
Secondary outcomes:
measure: Difference in tumor necrosis factor alpha (TNF-alfa)
timeFrame: 4 hours
measure: Difference between serum levels of total antioxidant capacity (TAC) at preoperative and postoperative period.
timeFrame: 4 hours
measure: Difference between serum levels of total oxidant capacity (TOC) at preoperative and postoperative period.
timeFrame: 4 hours
measure: Difference in c-reactive protein (CRP)
timeFrame: 24 hours
measure: Difference in alanine aminotransferase (ALT)
timeFrame: 24 hours
measure: Difference in aspartate aminotransferase (AST)
timeFrame: 24 hours
measure: Difference in creatinine
timeFrame: 24 hours
measure: Differences in preoperative State-Trait Anxiety Inventory scores
timeFrame: 20 minutes
measure: Differences in postoperative State-Trait Anxiety Inventory scores
timeFrame: 20 minutes
measure: Differences in pain scores
timeFrame: 24 hours
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istinye University Hospital
Study officials:
affiliation: Istinye University
name: Beyza Zeynep Kocabicak
role: PRINCIPAL_INVESTIGATOR
affiliation: Istinye University
name: Ali Sait Kavakli, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: İstinye University
name: Taylan Sahin, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00165386: MRI-guided Bone Marrow Biopsies of Prostate Cancer Patients
Official title: MRI-guided Bone Marrow Biopsies of Advanced CaP Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prostate Cancer
Keywords: MRI-guided bone marrow biopsy
Lead sponsor: Dana-Farber Cancer Institute
Sponsor class: OTHER
First posted: 2005-09-14
Enrollment: 20
Sex: MALE
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to target lesions of the prostate in the bone and to biopsy these lesions using MRI to identify the areas.

Detailed description: * This study involves a one-time, MRI-guided bone marrow biopsy. Prior to this procedure, patients will need to have a bone scan performed within the last three months and a PSA blood test drawn within one month of registration to the study.
* Patients are also required to participate in the DFCI research study "Collection of Specimens and Clinical Data for Patients with Prostate Cancer or at High Risk for Prostate Cancer".

Eligibility criteria: Inclusion Criteria:

* Histologic diagnosis of prostate cancer
* Bone scan consistent with or suspicious of metastatic prostate cancer within last three months
* Platelet count \> 50,000/ul
* PT and aPTT \< 1.5 x control
* At least one week removed from taking aspirin or coumadin
* Currently participating in protocol "Collection of Specimens and Clinical Data for Patients with Prostate Cancer or at High Risk for Prostate Cancer"

Exclusion Criteria:

* Devices incompatible to MR studies (e.g. pacemakers, ear implants, etc.)

Primary outcomes:
measure: To compare the yield of detecting metastatic prostate cancer tissue using MRI-guided bone marrow needle biopsies to that of historical controls obtained through unguided biopsies.
Secondary outcomes:
measure: To evaluate the sensitivity of radiographic bone marrow changes detected by MRI for prostate cancer, as determined by the pathologic findings from bone marrow biopsy.
Other outcomes:
Locations:
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
Study officials:
affiliation: Dana-Farber Cancer Institute
name: Mary-Ellen Taplin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03380286: IRIS-Firehawk® Cohort in the IRIS-DES Registry
Official title: Evaluation of Effectiveness and Safety of Firehawk® Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Coronary Stenosis
Coronary Disease
Keywords: Firehawk
Coronary Artery Disease
Drug Eluting Stent
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
Collaborators: name: CardioVascular Research Foundation, Korea
First posted: 2017-12-21
Enrollment: 0
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patient with Firehawk® coronary stent

Brief summary: The objective of this study is to evaluate effectiveness and safety of Firehawk® stent in the "real world" daily practice as compared with other drug-eluting stents.


Eligibility criteria: Inclusion Criteria:

* Age 19 and more
* Patient with Firehawk® coronary stent

Exclusion Criteria:

* Intervention with Firehawk® coronary stent and other drug eluting stent at the same time
* Life-expectancy less than 1 year
* Cardiac shock

Primary outcomes:
measure: Composite event rate of death, non-fatal myocardial infarction (MI), or Target- Vessel Revascularization (TVR)
timeFrame: 1 year
Secondary outcomes:
measure: All cause death
timeFrame: 5 year
measure: Cardiac death
timeFrame: 5 year
measure: Myocardial Infarction
timeFrame: 5 year
measure: Composite event rate of death or myocardial infarction (MI)
timeFrame: 5 year
measure: Composite event rate of cardiac death or myocardial infarction (MI)
timeFrame: 5 year
measure: Target- Vessel Revascularization
timeFrame: 5 year
measure: Target- Lesion Revascularization
timeFrame: 5 year
measure: Stent thrombosis
timeFrame: 5 year
measure: Procedural Success rate
timeFrame: 5 year
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
References:
Clinical trial NCT04677686: Observation of the Implementation of a Bundle of Care in Colorectal Surgery to Reduce Surgical Site Infections Successfully
Official title: Observation of the Implementation of a Bundle of Care in Colorectal Surgery to Reduce Surgical Site Infections Successfully
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Reduction of Surgical Site Infections in Colorectal Surgery
Keywords: colorectal surgery
bundle of care
surgical site infection
Lead sponsor: Luzerner Kantonsspital
Sponsor class: OTHER
First posted: 2020-12-21
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients undergoing colorectal surgery in the Cantonal Hospital of Lucerne October 2020-September 2021

Brief summary: This study aims to evaluate whether the colorectal bundle designed and implemented at Cantonal Hospital Lucerne, will lead to a significant reduction of SSIs. The impact of potential risk factors for SSIs will additionally be evaluated.

Detailed description: Surgical site infections (SSIs) remain a relevant problem in colorectal surgery. The aim of this study is to implement a bundle of care in order to reduce SSIs in colorectal surgery.

All patients undergoing colorectal surgery between October 2018 and September 2021 will be included in a prospective observational study. Since our colorectal bundle has been established gradually, patients will be grouped in a pre-implementation (2018-2019), implementation (2019-2020) and post implementation phase (2020-2021), in order to assess the effectiveness of the actions undertaken. Primary endpoint of this study will be surgical site infection (SSI) rate, while secondary endpoints encompass potential risk factors for SSIs. We assume that obesity, age, diabetes, alcoholism and smoking may lead to a higher risk for SSIs.

Eligibility criteria: Inclusion Criteria:

over 18 elective or emergency colorectal surgery written informed consent

Exclusion Criteria:

pregnant no informed consent

Primary outcomes:
measure: Surgical Site infection
timeFrame: 30 days
Secondary outcomes:
measure: Risk factors for SSI
timeFrame: at surgery
Other outcomes:
Locations:
city: Lucerne
country: Switzerland
facility: Cantonal Hospital of Lucerne
Study officials:
affiliation: Cantonal Hospital of Lucerne, Spitalstrasse, 6000 Lucerne 16
name: Jörn-Markus Gass
role: PRINCIPAL_INVESTIGATOR
References:
citation: Brunner S, Liesenberg J, Fourie L, Metzger J, Scheiwiller A, Zschokke I, Lehnick D, Gass JM. Implementation of a Bundle of Care in Colorectal Surgery to Reduce Surgical Site Infections Successfully at Cantonal Hospital Lucerne: Study Protocol for a Prospective Observational Study. Int J Surg Protoc. 2021 Sep 23;25(1):220-226. doi: 10.29337/ijsp.150. eCollection 2021.
Clinical trial NCT01412086: Inter-rater and Intra-rater Reliability of the Global Eyebrow Assessment Scale
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Volunteers
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2011-08-09
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy Volunteers

Brief summary: This study evaluated the inter- and intra-rater reliability of the GEBA Scale with photonumeric guide for the assessment of overall eyebrow fullness. There is no treatment (intervention) associated with this study.


Eligibility criteria: Inclusion Criteria:

* Willing to remove makeup and jewelry at each visit
* Willing to have photographs taken of the facial area

Exclusion Criteria:

* Permanent eyebrow makeup (i.e., tattooing) or eyebrow implants of any kind
* Eyebrow extension application within 3 months of study entry
* Eyebrow tint or dye application within 2 months of study entry
* Eyebrow grooming (i.e., tweezing, waxing, or threading) between visits that is not part of the current routine

Primary outcomes:
measure: Inter-rater Reliability of Physician Raters Using the Global Eyebrow Assessment (GEBA) Scale
timeFrame: Day 1
measure: Intra-rater Reliability of Physician Raters Using the Global Eyebrow Assessment (GEBA) Scale
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Newport Beach
country: United States
state: California
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT03446586: Hereditary Hepatorenal Tyrosinemia Natural History in Egypt and the Arab World (Multicenter Clinical Study)
Official title: Hereditary Hepatorenal Tyrosinemia Natural History (Multicenter Clinical Study): Registry for Patients With Tyrosinemia Type I in Egypt and the Arab World
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hereditary Tyrosinemia, Type I
Lead sponsor: Yassin Abdelghaffar Charity Center for Liver Disease and Research
Sponsor class: OTHER
Collaborators: name: Society of Friends of Liver Patients in the Arab World (SLPAW)
First posted: 2018-02-27
Enrollment: 50
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with tyrosinemia type I seen by one of the participating sites.

Brief summary: The purpose of the registry/repository is to understand the natural history of tyrosinemia in our region and to provide a mechanism to store data and specimens to support the conduct of future research about hereditary tyrosinemia among the Arabs.

Detailed description: The purpose of this study is to create an electronic registry of phenotypic, laboratory information, treatment and outcomes options for tyrosinemia type I. The registry is longitudinal in nature including retrospective clinical data from birth to the most recent encounter with all data entered in chronological fashion. The goals of this registry are the better understanding of the natural history and treatment outcomes of these patients and to determine/evaluate biochemical and clinical parameters for monitoring and prognosis of tyrosinemia type I.

Eligibility criteria: Inclusion Criteria:

1. Biochemical or molecular diagnosis of Tyrosinemia Type I.
2. Examined/followed by one of the participating sites.
3. Parental/guardian permission (informed consent) for participation.

Exclusion Criteria:

1. Diagnosis of tyrosinemia has been excluded.
2. Not examined/followed by one of the participating sites.
3. Unwilling to provide informed consent for participation.

Primary outcomes:
measure: Create a registry for tyrosinemia type I.
timeFrame: 5 Years
Secondary outcomes:
Other outcomes:
Locations:
city: Nasr City
country: Egypt
facility: Professor Yassin Abdel Ghaffar Charity Center for Liver Disease and Research
state: Cairo
Study officials:
affiliation: Yassin Abdelghaffar Charity Center for Liver Disease and Research
name: Tawhida Y Abdelghaffar, MD
role: PRINCIPAL_INVESTIGATOR
References: